• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • FDA Considers Withdrawing Makena Approval americanpharmaceuticalreview
    October 10, 2020
    AMAG Pharmaceuticals has received a notice from the U.S. Food and Drug Administration (FDA) that the FDA is proposing to withdraw approval of Makena® (hydroxyprogesterone caproate injection).
  • AMAG's confirmatory study of Makena to reduce risk of preterm birth misses main goals biospectrumasia
    March 11, 2019
    AMAG Pharmaceuticals said Friday that a confirmatory study of Makena (hydroxyprogesterone caproate) in patients with a history of a prior spontaneous singleton preterm delivery failed to meet its co-primary endpoints. Shares in the company, which gained a

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service